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In this issue of Cancer Cell, Gascoigne and Taylor (2008) report their findings of following 10,000 single cells
incubated with three classes of antimitotic drugs, including paclitaxel (taxol). This extensive analysis reveals
a previously unappreciated complexity in response to such drugs and demonstrates that it is more than
genetics that determines cell life or death.To maintain its chromosome content,
each dividing cell must partition its repli-
cated genome such that one copy of
each chromosome is deposited into
each new daughter cell. Errors in this pro-
cess lead to the production of aneuploid
daughter cells that contain an abnormal
chromosome content. Aneuploidy can
have drastic consequences for both the
cell and the organism (Kops et al., 2005).
Indeed, while most aneuploid human em-
bryos are inviable, those that do survive
develop severe birth defects such as
Down’s syndrome (Jacobs and Hassold,
1995). Furthermore, aneuploidy is a com-
mon characteristic of tumor cells and has
been shown in some instances to play
a causative role in the development of
cancer (Weaver et al., 2007).
A major safeguard for protecting cells
against chromosome missegregation is
the mitotic checkpoint (also known as the
spindle assembly checkpoint) (Kops et al.,
2005; Musacchio and Salmon, 2007). This
cell-cycle control mechanism operates in
every mitosis to ensure the faithful parti-
tioning of the duplicated chromosomes
between the two daughter cells. Chromo-
somes are sorted in mitosis by the microtu-
bule spindle, to which they attach at a
specialized protein structure known as
the kinetochore. Unattached kinetochores
are the source of the mitotic checkpoint
signal and act by producing an inhibitor
that delays cyclin B1 degradation and
chromosome segregation until all chromo-
somes have stably attached to the spindle.
Some drugs that target the mitotic
checkpoint have a long history as suc-
cessful anticancer agents and are com-
monly used in the treatment of a variety
of human cancers (Jackson et al., 2007).These agents, known as antimitotic
drugs, generally act by chronically acti-
vating the mitotic checkpoint, leading to
a prolonged mitotic delay (Rieder and
Maiato, 2004). There are several possible
outcomes of this drug-induced mitotic
delay. Cells may undergo death while ar-
rested in mitosis or exit mitosis in the
presence of the drug and transition into
the subsequent interphase, a process
known as adaptation. Filming of cyclin
B1 levels in living cells has suggested
that cyclin B1 is progressively lost during
a mitotic delay (Brito and Rieder, 2006).
Eventually, cyclin B1 levels fall below the
threshold required to maintain mitotic ar-
rest and adaptation occurs. Adapted cells
may then continue to cycle, senesce, or
execute death pathways from interphase.
Despite the clinical importance of pre-
dicting which tumors will show favorable
responses to antimitotic drugs, the path-
ways that determine whether a cell dies,
arrests, or proliferates following treatment
with antimitotic drugs are not known
(Rieder and Maiato, 2004).
Determining Cell Fate
In this issue, Gascoigne and Taylor (2008)
provide the most in-depth analysis to date
of the response of cancer cells to antimi-
totic agents. Utilizing high-throughput
automated time-lapse microscopy, the
authors determined the response of indi-
vidual cells from a large panel of tumor
cell lines treated with three classes of an-
timitotic drugs. As anticipated from ear-
lier work, different tumor cell lines varied
widely in their response to antimitotic
agents. Surprisingly, however, cells within
the same line often also displayed sub-
stantial variation in their response toCancer Celldrug treatment. The authors elegantly and
persuasively demonstrate that the varia-
tion in the fate of individual cells within
a population cannot be accounted for by
initial genetic variation. Indeed, even pre-
sumably genetically identical daughter
cells frequently behave differently in the
next mitosis, varying in their response as
much as two cells chosen at random from
the population. Thus, cell fate in response
to chronic mitotic checkpoint activation is
not genetically predetermined. Instead,
Gascoigne and Taylor’s observations im-
plicate an unexpected level of stochastic
variation in the signaling pathways acti-
vated by antimitotic agents.
Having demonstrated tremendous vari-
ation in the behavior of cells to antimitotic
agents, Gascoigne and Taylor formulate
and test a model in which mitotic cell
fate is determined by two competing net-
works, one involving the slow destruction
of cyclin B1, the other the progressive ac-
tivation of a putative caspase-dependent
death pathway. By establishing the thre-
shold level of cyclin B1 that is required
for mitotic exit, the authors demonstrate
that cells that typically die directly from
mitosis only slowly degrade cyclin B1,
thereby failing to breach the threshold re-
quired for mitotic exit prior to death
(Figure 1B). By contrast, cells that un-
dergo adaptation progressively destroy
cyclin B1 and surpass this threshold,
leading to mitotic exit (Figure 1A). For
each cell line tested, inhibiting caspase
activation with a pan-caspase inhibitor
not only reduced the proportion of cells
that died in mitosis but also prolonged
the duration of the mitotic arrest. This sug-
gests that by inhibiting caspase-depen-
dent death signals produced by chronic14, August 12, 2008 ª2008 Elsevier Inc. 103
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(A) Cyclin B1 (blue) is progressively destroyed during a mitotic delay, and at the same time, a putative
death signal (red; possibly also produced by the mitotic checkpoint) accumulates. Eventually, cyclin B1
levels fall bellow a threshold required to maintain mitotic arrest, and the cell undergoes adaptation.
(B) Cyclin B1 levels fall during mitotic delay but fail to decline to the threshold required to allow mitotic exit.
Instead, the apoptotic signal reaches a level sufficient to promote cell death in mitosis.
(C) Slowing the activation of apoptotic effectors by treatment with a caspase inhibitor provides a cell with
more time to destroy cyclin B1. This allows cyclin B1 levels to reach the threshold required to promote
mitotic exit before apoptosis is initiated.mitotic checkpoint signaling, cells are
provided with more time to degrade cyclin
B1 to a level sufficient to promote mitotic
exit (Figure 1C).
Chromosomal Instability Revisited
Aneuploidy is a remarkably common char-
acteristic of tumor cells often resulting
from an underlying chromosomal instabil-
ity (CIN), characterized by frequent gains
and losses of chromosomes during cell
division (Kops et al., 2005). A long-stand-
ing, widely held view is that chromoso-
mally unstable cancer cells possess
a weakened mitotic checkpoint that per-
mits the onset of anaphase in the pres-
ence of misaligned chromosomes. This
dogma was challenged in a recent study
showing that CIN cells do not prematurely
initiate anaphase but rather exhibit an
increased incidence of lagging anaphase104 Cancer Cell 14, August 12, 2008 ª2008 Echromosomes (Thompson and Compton,
2008). Gascoigne and Taylor (2008) con-
firm these observations and further dem-
onstrate that CIN cells arrest in mitosis
for as long as chromosomally stable cell
lines. Taking the results of these studies
together, the evidence is now compelling
that the mitotic checkpoint is not compro-
mised in chromosomally unstable cancer
cells. Moreover, the detailed single-cell
analysis dispels the proposal that CIN
cells are more sensitive to the killing ac-
tion of antimitotic drugs.
Utilizing their extensive data set, Gas-
coigne and Taylor further explore the
widely held view that the duration of mi-
totic delay may dictate the subsequent
cellular response. Importantly, however,
no correlation was found between length
of delay and resulting cell fate. This con-
curs with a recent report showing thatlsevier Inc.the ability of the mitotic checkpoint to de-
lay cells in mitosis is a poor predictor of
cellular response to antimitotic drugs
(Shi et al., 2008). Rather, cell fate was
found to correlate much more closely
with the sensitivity of cell lines to apopto-
sis induced by other factors, such as the
broad-spectrum kinase inhibitor stauro-
sporine (Shi et al., 2008). This implies
that sensitivity to apoptotic signaling
may be an important source of variation
in the response of cancer cells to antimi-
totic drugs and suggests that more favor-
able drug responses may be achieved by
combining antimitotic drugs with agents
that restore apoptotic pathways in death-
resistant cells.
Future Directions
Previous studies investigating cell fate in
response to antimitotic agents have pre-
dominantly relied upon indirect assays
that average the responses of populations
of cells. The enhanced resolution afforded
by direct single-cell assays has now re-
vealed that these prior studies have dra-
matically underestimated the variation in
cell fate in response to antimitotic drugs.
Central questions now raised, but still left
unanswered, include: What is the identity
of the putative death signal that accumu-
lates during a mitotic delay? What are the
relative thresholds of cyclin B1 and apo-
ptotic signaling required to promote adap-
tation and death in various cell lines? What
are the pathways responsible for deter-
mining cell fate following adaptation, and
why do some cell lines show dramatically
different responses to different antimitotic
drugs that all chronically activate the mi-
totic checkpoint? Finally, it is important to
bear in mind that the in vitro conditions
used here fail to recapitulate aspects of
the tumor microenvironment that may
have important influences on cell fate in-
cluding, for example, drug clearance by
the circulation, which would lead to re-
newed cell cycling. Indeed, knowing that
stochastic processes can be central to
the cell’s decision to live or die leaves
open the question as to how closely the
response of cell lines will model the fate
of a heterogeneous population of tumor
cells.
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The cellular origins of most solid tumors
are not well understood, in part because
specific markers for the stem, progenitor,
and differentiated cell populations from
which they might arise are often lacking.
Medulloblastomas are central nervous
system (CNS) embryonal tumors com-
posed of primitive-appearing cells that
can differentiate along multiple lineages
(Louis et al., 2007). They arise in the cere-
bellum, but it is not yet clear whether
multipotent stem cells, developmentally
restricted progenitors, or other cells give
rise to these pediatric malignancies. It is
hoped that by defining the cell (or cells)
in which they form and the relationship
between normal development and onco-
genesis, improved therapies can be
developed.
The cerebellar ventricular zone (VZ)
consists of a band of stem and progenitor
cells that line the IVth ventricle of the cer-
ebellum (Figure 1). It gives rise to most cell
types in the cerebellum, including Berg-
mann glia, astrocytes, oligodendrocytes,
and Purkinje neurons (Sillitoe and Joyner,
2007). At one edge of this zone lies the
rhombic lip, which sends forth a stream
of lineage-restricted granule neuron pre-
cursors (GNPs) over the cerebellar sur-Kops, G.J., Weaver, B.A., and Cleveland, D.W.
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face. These proliferate transiently in the
external germinal/granular layer (EGL)
and then migrate inward and differentiate
to form the numerous small neurons of the
internal granule cell layer (IGL).
It has become clear that many molecu-
lar pathways play similar roles in both
cerebellar development and medulloblas-
toma formation. Hedgehog signaling, for
example, drives proliferation of the cere-
bellar EGL and is also activated in both
familial and sporadic medulloblastomas,
most commonly by mutations or deletions
abrogating function of the inhibitory re-
ceptor Patched (Ptc) (Louis et al., 2007;
Pietsch et al., 1997). Transgenic mice
lacking one copy of Ptc develop medullo-
blastomas that appear to arise from prolif-
erations of GNP-like cells in the EGL (Kho
et al., 2004; Oliver et al., 2005), suggesting
that medulloblastomas form in lineage-
committed progenitor cells. However,
this notion must be reconciled with the
fact that medulloblastomas are thought
to differentiate into both glia and neurons,
occasionally even forming melanocytic or
muscle cells (Louis et al., 2007). While
such a broad cellular spectrum could re-
sult from dedifferentiation of a committed
GNP due to the influence of oncogenic
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that Hedgehog activation in either
causes only medulloblastomas to
mit to a specific lineage in order
molecular events, it is also possible that
the tumors truly form in multipotent stem
cells with an intrinsic multilineage poten-
tial. Indeed, several studies have sug-
gested that some medulloblastomas ex-
press markers normally found in VZ stem
cells and their descendants, but this is
not proof that the tumors came from
stem cells (Eberhart, 2007).
In this issue of Cancer Cell, Yang et al.
(2008) and Schu¨ller et al. (2008) directly
address the issue of which CNS cells are
capable of being transformed into tumors
by Hedgehog activation. They find that
while neoplasms can be ‘‘initiated’’ when
genetic changes are induced in either
multipotent VZ cells or lineage-committed
cells, tumor masses appear to first form
in the EGL and have a largely GNP-like
phenotype.
Yang and colleagues (2008) use condi-
tional cre-mediated deletion of Ptc in
knockout mice (PtcC/C) to activate the
Hedgehog pathway in eitherGNPsormulti-
potent stem cells. Activation in Math1-
expressing GNPs of the rhombic lip and
EGL resulted ina markedexpansionand in-
appropriate persistence of this progenitor
layer during early postnatal life. Many of
these cells were able to exit the cell cycle,
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